PCRX Pacira BioSciences Inc.

45.35
-0.95  -2%
Previous Close 46.3
Open 46.14
Price To Book 5.46
Market Cap 1,892,492,097
Shares 41,730,807
Volume 442,101
Short Ratio
Av. Daily Volume 828,844
Stock charts supplied by TradingView

NewsSee all news

  1. Pacira BioSciences to Present at the 31st Annual Piper Jaffray Healthcare Conference

    PARSIPPANY, N.J., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today reported that it will present at the 31st Annual Piper Jaffray Healthcare Conference at 9:30 AM on Tuesday, December 3,

  2. Pacira BioSciences to Present at the Jefferies 2019 London Healthcare Conference

    PARSIPPANY, N.J., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today reported that it will present at the Jefferies 2019 London Healthcare Conference at 2:40 PM GMT (9:40AM ET) on Wednesday,

  3. Pacira BioSciences Reports Third Quarter 2019 Financial Results and Business Update

    -- Total revenues increased 25 percent over prior year to $104.7 million in third quarter -- -- Conference call today at 8:30 a.m. ET -- PARSIPPANY, N.J., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc.

  4. Pacira to Report Third Quarter 2019 Financial Results on Thursday November 7, 2019

    PARSIPPANY, N.J., Oct. 25, 2019 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its third quarter financial results before the open of the U.S. markets on Thursday,

  5. Pacira BioSciences Set to Join S&P SmallCap 600

    NEW YORK, Sept. 24, 2019 /PRNewswire/ -- Pacira BioSciences Inc. (NASD: PCRX) will replace Shutterfly Inc. (NASD: SFLY) in the S&P SmallCap 600 effective prior to the open of trading on Monday, September 30. Apollo

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Approved October 31, 2011.
EXPAREL
Postsurgical pain
Approval announced April 6, 2018.
EXPAREL
Post surgical pain
Phase 3 data due 4Q 2019.
EXPAREL - pediatric patients
Postoperative Pain Management

Latest News

  1. Pacira BioSciences to Present at the 31st Annual Piper Jaffray Healthcare Conference

    PARSIPPANY, N.J., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today reported that it will present at the 31st Annual Piper Jaffray Healthcare Conference at 9:30 AM on Tuesday, December 3,

  2. Pacira BioSciences to Present at the Jefferies 2019 London Healthcare Conference

    PARSIPPANY, N.J., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today reported that it will present at the Jefferies 2019 London Healthcare Conference at 2:40 PM GMT (9:40AM ET) on Wednesday,

  3. Pacira BioSciences Reports Third Quarter 2019 Financial Results and Business Update

    -- Total revenues increased 25 percent over prior year to $104.7 million in third quarter -- -- Conference call today at 8:30 a.m. ET -- PARSIPPANY, N.J., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc.

  4. Pacira to Report Third Quarter 2019 Financial Results on Thursday November 7, 2019

    PARSIPPANY, N.J., Oct. 25, 2019 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its third quarter financial results before the open of the U.S. markets on Thursday,

  5. Pacira BioSciences Set to Join S&P SmallCap 600

    NEW YORK, Sept. 24, 2019 /PRNewswire/ -- Pacira BioSciences Inc. (NASD: PCRX) will replace Shutterfly Inc. (NASD: SFLY) in the S&P SmallCap 600 effective prior to the open of trading on Monday, September 30. Apollo

  6. Pacira BioSciences Appoints Chris Christie to Board of Directors

    PARSIPPANY, N.J., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), a leading provider of innovative non-opioid pain management options, today announced the appointment of Christopher J.

  7. Pacira BioSciences Completes Enrollment in Multicenter Registration Study of EXPAREL® in Pediatric Patients

    PARSIPPANY, N.J., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), a leading provider of innovative non-opioid pain management options, today announced that it has reached full enrollment of